(Reuters) – Japan’s Astellas Pharma said on Monday it had fully acquired drugmaker IVERIC Bio Inc, through Berry Merger Sub, Inc, a wholly-owned subsidiary of Astellas US Holding, Inc.
Astellas bought IVERIC for $40.00 per share in cash, for a total equity value of approximately $5.9 billion.
(Reporting by Baranjot Kaur in Bengaluru; Editing by Kim Coghill)
